Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study

Van Der Valk, Paul, Makris, Michael, Fischer, Kathelijn, Tait, Robert C., Chowdary, Pratima, Collins, Peter W. ORCID: https://orcid.org/0000-0002-6410-1324, Meijer, Karina, van Vulpen, Lize F. D., Mauser-Bunschoten, Eveline and Schutgens, Roger E. G. 2022. Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study. Blood Advances 6 (3) , pp. 902-908. 10.1182/bloodadvances.2021005260

Preview

PDF - Published Version Download (898kB) | Preview

Abstract

Hemophilia is a congenital bleeding disorder caused by low levels of clotting factor VIII or IX. The life expectancy of people with hemophilia (PWH) has increased with the availability of clotting factor concentrates. At the same time, the incidence of cardiovascular disease (CVD) has increased; in retrospective studies, there are conflicting data regarding if, despite this increase, the incidence is still lower than in the general population. We prospectively compared the incidence of CVD in PWH vs the predicted incidence. This prospective, multicenter, observational study included adult PWH (aged >30 years) from The Netherlands and United Kingdom. They were followed up for a 5-year period, and CVD incidence was compared with a predicted event rate based on the QRISK2-2011 CVD risk model. The primary end point was the observed fatal and nonfatal CVD incidence after 5 years compared with the estimated events and in relation to severity of hemophilia. The study included 709 patients, of whom 687 (96.9%) completed 5 years’ follow-up or reached an end point. For 108 patients, the QRISK score could not be calculated at inclusion. For the remaining 579, fewer CVD events were observed than predicted: 9 vs 24 (relative risk, 0.38; 95% confidence interval, 0.18-0.80; P = .01), corresponding with an absolute risk reduction of 2.4%. Severe hemophilia treated on demand had the highest risk reduction. There was no statistically significant relation between severity of hemophilia and incidence of CVD. In hemophilia, a lower-than-predicted CVD incidence was found, supporting the theory that hemophilia protects against CVD. The study is registered at www.clinicaltrials.gov as #NCT01303900.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	American Society of Hematology
ISSN:	2473-9529
Date of First Compliant Deposit:	16 June 2022
Date of Acceptance:	8 November 2021
Last Modified:	24 May 2023 00:08
URI:	https://orca.cardiff.ac.uk/id/eprint/150542

Citation Data

Cited 5 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item